Table 1.
Clinical characteristics of 56 enrolled ccRCC patients with first-line TKIs therapy
| Clinical Characteristics | Overall | DDR alteration | VHL alteration | VHL + DDR co-mutation |
|---|---|---|---|---|
| No. of patients | 56 | 17 | 35 | 13 |
| Median yrs age of at initiation of therapy(years), (range) | 56(24–79) | 56(41–79) | 59(36–73) | 56(41–73) |
| Gender(male) | 43(76.79%) | 12(70.59%) | 26(74.29%) | 8(61.54%) |
| Sarcomatoid | 4(7.14%) | 1(5.88%) | 3(8.57%) | 1(7.69%) |
| IMDC risk score | ||||
| Favorable | 1(1.79%) | 1(5.88%) | 0(0%) | 0(0%) |
| Intermediate | 42(75.00%) | 16(94.12%) | 28(80%) | 13(100%) |
| Poor | 13(23.21%) | 0(0%) | 7(20%) | 0(0%) |
| MSKCC risk score | ||||
| Favorable | 1(1.79%) | 1(5.88%) | 0(0%) | 0(0%) |
| Intermediate | 46(82.14%) | 16(94.12%) | 31(88.57%) | 13(100%) |
| Poor | 9(16.07%) | 0(0%) | 4(11.43%) | 0(0%) |
| VEGF-TKI agent | ||||
| Sunitinib | 18(32.14%) | 7(41.18%) | 10(28.57%) | 5(38.46%) |
| Pazopanib | 6(10.71%) | 0(0%) | 3(8.57%) | 0(0%) |
| Axitinib | 11(19.64%) | 4(23.53%) | 10(28.57%) | 7(53.85%) |
| Sorafenib | 21(37.50%) | 6(35.29%) | 12(34.29%) | 1(7.69%) |